Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China.
Liu Y, Zhang J, Liu W, Pan Y, Ruan S, Nian X, Chen W, Sun L, Yin Q, Yue X, Li Q, Gui F, Wu C, Wang S, Yang Y, Jing Z, Long F, Wang Z, Zhang Z, Huang C, Duan K, Liang M, Yang X.
Liu Y, et al. Among authors: chen w.
Emerg Microbes Infect. 2024 Dec;13(1):2284297. doi: 10.1080/22221751.2023.2284297. Epub 2024 Mar 26.
Emerg Microbes Infect. 2024.
PMID: 37970736
Free PMC article.
Clinical Trial.